Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers. Josting A, et al. Among authors: rudolph c. Ann Oncol. 2002 Oct;13(10):1628-35. doi: 10.1093/annonc/mdf221. Ann Oncol. 2002. PMID: 12377653 Free article. Clinical Trial.
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial.
Glossmann JP, Engert A, Wassmer G, Flechtner H, Ko Y, Rudolph C, Metzner B, Dörken B, Wiedenmann S, Diehl V, Josting A. Glossmann JP, et al. Among authors: rudolph c. Ann Hematol. 2003 Aug;82(8):469-475. doi: 10.1007/s00277-003-0695-0. Epub 2003 Jun 21. Ann Hematol. 2003. PMID: 12910374 Clinical Trial.
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A. Josting A, et al. Among authors: rudolph c. Ann Oncol. 2005 Jan;16(1):116-23. doi: 10.1093/annonc/mdi003. Ann Oncol. 2005. PMID: 15598948 Free article. Clinical Trial.
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Wunderlich A, et al. Among authors: rudolph c. Ann Oncol. 2003 Jun;14(6):881-93. doi: 10.1093/annonc/mdg249. Ann Oncol. 2003. PMID: 12796026 Free article. Clinical Trial.
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Pfreundschuh M, et al. Among authors: rudolph c. Blood. 2004 Aug 1;104(3):626-33. doi: 10.1182/blood-2003-06-2094. Epub 2004 Feb 24. Blood. 2004. PMID: 14982884 Free article. Clinical Trial.
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Pfreundschuh M, et al. Among authors: rudolph c. Blood. 2004 Aug 1;104(3):634-41. doi: 10.1182/blood-2003-06-2095. Epub 2004 Mar 11. Blood. 2004. PMID: 15016643 Free article. Clinical Trial.
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Hofmann WK, Seipelt G, Langenhan S, Reutzel R, Schott D, Schoeffski O, Illiger HJ, Hartmann F, Balleisen L, Franke A, Fiedler F, Huber C, Rasche H, Bergmann L, Ganser A, Pott C, Pasold R, Rudolph C, Ottmann OG, Gökbuget N, Hoelzer D. Hofmann WK, et al. Among authors: rudolph c. Ann Hematol. 2002 Oct;81(10):570-4. doi: 10.1007/s00277-002-0542-8. Epub 2002 Oct 17. Ann Hematol. 2002. PMID: 12424538 Clinical Trial.
581 results